Dr. Reddy’s Q2FY27 slides: base growth masks lenalidomide drag

Dr. Reddy’s Laboratories reported fiscal Q2 2027 revenues of ₹8,671 crores, down 1.5% YoY but up 7% sequentially. EBITDA margin was 20.6%, with profit after tax at ₹925 crores. North America sales declined 23% YoY due to lenalidomide, but other regions showed growth. The company announced strategic partnerships and product developments, including a dengue vaccine and biosimilars. Shares rose 0.45% to $13.29 post-results.

Original reporting
Published Oct 23, 2026, 3:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 3:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RDY
Neutral
high confidence
Mentioned
$RDY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RDYNeutralMed
01

Why it matters

Earnings provide fresh data on revenue, margins, and guidance, influencing short-term price action.

02

Market read

Earnings release offers modest trading opportunity; base growth may support price, but lenalidomide drag poses risk.

03

What to watch

Potential upside from upcoming biosimilar approvals and CDMO revenue growth.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Dr. Reddy's reported Q2FY27 results, highlighting base business growth and lenalidomide sales decline.

Company-level read

Ticker impact

$RDYNeutralHigh confidence
Context

Q2FY27 earnings released with revenue decline and lenalidomide sales drop, new guidance and margins disclosed.

Expected impact

likely slight upward pressure as investors view base growth positively, though lenalidomide drag could cap gains

Evidence & confidence

First report of quarterly results with fresh numbers; market reaction was a 0.45% rise, indicating limited but positive bias.

Market effects

Pharma sector may see mixed sentiment as generic growth offsets loss of lenalidomide exclusivity.

Indian market outlook improves with domestic revenue growth.

Limited, primarily affects RDY and peers in generics.

Counterpoint

Lenalidomide decline could signal broader margin pressure if other exclusivity losses follow.

Key entities

  • Dr. Reddy's Laboratories

    Indian pharmaceutical company reporting Q2FY27 results.

Related articles

$RDYHigh

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

$RDYMed

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia